Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment
TL;DR
Tonix Pharmaceuticals' TNX-102 SL offers a competitive edge in fibromyalgia treatment with its unique sublingual formulation promising enhanced efficacy and tolerability.
TNX-102 SL bypasses liver metabolism, achieving higher nighttime drug levels and lower metabolite accumulation, as shown in the RESILIENT Phase 3 trial.
TNX-102 SL could significantly improve the quality of life for fibromyalgia patients, marking a potential breakthrough in pain management and sleep improvement.
Discover how Tonix Pharmaceuticals' innovative TNX-102 SL could revolutionize fibromyalgia treatment with its novel approach and promising clinical trial results.
Found this article helpful?
Share it with your network and spread the knowledge!
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has unveiled positive Phase 3 trial results for its fibromyalgia drug, TNX-102 SL, at the 2025 Annual European Congress of Rheumatology (EULAR) in Barcelona. The data from the RESILIENT trial demonstrated statistically significant, sustained pain reduction over 14 weeks, alongside improved sleep quality and favorable tolerability. This sublingual formulation of cyclobenzaprine is designed to bypass first-pass liver metabolism, achieving higher nighttime drug levels and lower metabolite accumulation, which may enhance long-term efficacy.
The significance of this development lies in the potential of TNX-102 SL to become the first new fibromyalgia therapy in 15 years, addressing a critical unmet need for millions suffering from this chronic condition. With a Prescription Drug User Fee Act (PDUFA) goal date set for August 15, 2025, the drug's approval could mark a pivotal advancement in pain management, offering hope for improved quality of life for patients worldwide.
Curated from InvestorBrandNetwork (IBN)
